Clinical trials: Osteoporosis, Osteopenia
Postmenopausal Osteoporosis
Twenty-Four Month Extension Study of BA058-05-003 (Abaloparatide) in Participants With Osteoporosis
The purpose of this study is to provide 24 months of standard of care data on participants previously enrolled in Study BA058-05-003 (NCT02653417).
- Trial name
- ACTIVExtend (NCT01657162)
- Testing
- Alendronate
- Where
- 25 sites in United States, Argentina and 8 more
- Volunteers
- 1,139 people
- Sponsor
- Radius Health, Inc.
Spinal Cord Injury, Bone Loss
Effect of Alendronate on Bone in People With Chronic Spinal Cord Injury (SCI) Previously Treated With Teriparatide
The purpose of this study is to determine if a year of alendronate treatment will maintain or increase bone mass density (BMD) compared to baseline BMD values in people with chronic spinal cord injury (SCI).
- Conditions
- Spinal Cord Injury, Bone Loss, Osteoporosis
- Trial name
- NCT02195895
- Testing
- Alendronate, Calcium, Vitamin D
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Northwestern University
Osteoporosis
Study Evaluating Changes In Bone Mineral Density (BMD), And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD
The main purpose of this study is to assess whether a locally-administered rhBMP-2/CPM injection can rapidly increase bone mass in subjects at high risk for osteoporotic fractures of the hip.
- Trial name
- NCT00752557
- Testing
- rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy), bisphosphonates, calcium, and vitamin D
- Where
- 35 sites in United States, Belgium and 2 more
- Volunteers
- 50 people
- Sponsor
- Pfizer
Osteopenia, Osteoporosis
Prevention of Bone Loss After Pediatric Hematopoietic Cell Transplantation
This is a Phase 2, open-label, randomized, controlled clinical study of pediatric subjects treated with pamidronate with calcium and vitamin D versus calcium and vitamin D alone following hematopoietic cell transplantation (HCT).
- Trial name
- NCT02074631
- Testing
- Pamidronate, Calcium and vitamin D
- Where
- 2 sites in United States
- Volunteers
- 63 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Osteoporosis, Chronic Kidney Disease
Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients
The primary objective of the study is to examine the effect of denosumab on lumbar spine bone mineral density (BMD) after one year of treatment in newly transplanted renal allograft recipients.
- Trial name
- POSTOP (NCT01377467)
- Testing
- Denosumab (Prolia)
- Where
- Switzerland
- Volunteers
- 90 people
- Sponsor
- Rudolf Wuethrich
Anorexia Nervosa, Osteopenia
IGF-1 and Bone Loss in Women With Anorexia Nervosa
Anorexia nervosa is an eating disorder that can cause thinning of the bones (a decrease in bone density). A significant decrease in bone density is called osteopenia or osteoporosis.
- Conditions
- Anorexia Nervosa, Osteopenia, Osteoporosis
- Trial name
- NCT01406444
- Testing
- rhIGF-1, Risedronate
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- Massachusetts General Hospital
Cancer, Cataract
Evaluation of New or Worsening Lens Opacifications in Men With Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss
This is a phase 3, randomized, double-blind, placebo-controlled study to evaluate new or worsening lens opacifications in men with non-metastatic prostate cancer receiving denosumab for bone loss due to androgen deprivation…
- Conditions
- Cancer, Cataract, Low Bone Mineral Density, Osteopenia
- Trial name
- NCT00925600
- Testing
- Denosumab
- Where
- 172 sites in United States, Australia and 16 more
- Volunteers
- 769 people
- Sponsor
- Amgen
Low Bone Mass, Low Bone Mineral Density
Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis
The purpose of this study is to assess how effective and safe denosumab is in a population of males with low bone mass at risk of fracture.
- Conditions
- Low Bone Mass, Low Bone Mineral Density, Males With Osteoporosis, Osteopenia
- Trial name
- NCT00980174
- Testing
- 60 mg denosumab
- Volunteers
- 242 people
- Sponsor
- Amgen
HIV, Osteopenia
Switch From Tenofovir to Raltegravir for Low Bone Mineral Density
The purpose of this study is to determine if low bone mineral density (a measurement of how thick and strong bones are) improves in adults with HIV infection who switch their HIV medication tenofovir to another HIV medication…
- Conditions
- HIV, Osteopenia, Osteoporosis, HIV Infections
- Trial name
- TROP (NCT00939874)
- Testing
- Raltegravir
- Where
- 4 sites in Australia
- Volunteers
- 52 people
- Sponsor
- St Vincent's Hospital, Sydney
Obesity, Weight Loss
Utilizing Protein During Weight Loss to Impact Physical Function and Bone
This study is an ancillary study to the Utilizing Protein During Weight Loss to Impact Physical Function (UPLIFT) trial (NCT03074643) to evaluate the effects of diet composition (i.e., amount of protein and carbohydrate) during a…
- Conditions
- Obesity, Weight Loss, Diet Modification, Aging
- Trial name
- UPLIFT-Bone (NCT03819478)
- Testing
- Weight loss intervention months 0-6, Exercise intervention months 0-6, NutraBio™ CarboMax Supplement
- Where
- United States
- Volunteers
- 187 people
- Sponsor
- Wake Forest University Health Sciences
HIV Infection, Bone Loss
Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV)
With the increasing age of people living with HIV/AIDS, age-induced osteoporosis is likely to be compounded by HIV/AIDS and HAART-associated bone loss.
- Conditions
- HIV Infection, Bone Loss, Osteopenia, Osteoporosis
- Trial name
- BLIR-HIV (NCT01228318)
- Testing
- Zoledronic acid
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Emory University
Postmenopausal, Osteopenia
Effects of Denosumab on the Pharmacokinetics of Etanercept
The primary objective of the study was to characterize the effects of a single dose of denosumab on the pharmacokinetics (PK) of etanercept in postmenopausal women with low bone mineral density (BMD) and rheumatoid arthritis…
- Conditions
- Postmenopausal, Osteopenia, Rheumatoid Arthritis, Osteoporosis
- Trial name
- NCT01294397
- Testing
- Etanercept, Denosumab
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Amgen
Osteopenia, Osteoporosis
Safety And Tolerability Study Of RN564 In Women With Osteopenia And Healthy Men.
The purpose of this study is to determine the safety and tolerability of RN564 in women with osteopenia and healthy men.
- Conditions
- Osteopenia, Osteoporosis, Bone Disease
- Trial name
- NCT01293487
- Testing
- RN564
- Where
- 8 sites in United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Pfizer
Spinal Cord Injury, Acute Spinal Cord Injury
Prevention of Bone Loss After Acute SCI by Zoledronic Acid
The overall objective of this study is to define an effective therapeutic approach, using currently available medication, to prevent or mitigate the loss of bone mass and bone strength that occurs after acute spinal cord injury.
- Conditions
- Spinal Cord Injury, Acute Spinal Cord Injury, Bone Loss, Osteoporosis
- Trial name
- NCT02325414
- Testing
- Zoledronic acid
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Northwestern University
Osteopenia, Osteoporosis
Extension Study to Evaluate the Long Term Safety and Efficacy of Denosumab in the Treatment of Osteoporosis
The primary objective was to describe the safety and tolerability of up to 10 years or 7 years denosumab administration as measured by adverse event monitoring, immunogenicity and safety laboratory parameters in participants who…
- Trial name
- NCT00523341
- Testing
- Denosumab
- Volunteers
- 4,550 people
- Sponsor
- Amgen
Post-Menopausal Osteoporosis, Post-Menopausal Osteopenia
Vitamin K Supplementation in Post-Menopausal Osteopenia
The purpose of this study is to determine whether supplementation with 5 mg vitamin K daily over a 2-year period will prevent bone loss in post-menopausal women with osteopenia.
- Trial name
- NCT00150969
- Testing
- vitamin K1 (phylloquinone)
- Where
- 5 sites in Canada
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Osteoporosis
Impact of Vitamin D Supplementation on Lactation Associated Bone Loss
Studies have shown that lactation is associated with a loss of bone density from four to seven percent at the spine and hip among women who lactate for six months. Decline in bone density with lactation occurs rapidly.
- Trial name
- NCT00903344
- Testing
- Vitamin D3, Multivitamin
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Leigh Eck, MD
Menopause, Osteoporosis
Using Soy Estrogens to Prevent Bone Loss and Other Menopausal Symptoms
The purpose of this study is to determine if soy-derived phytoestrogens (naturally occurring compounds similar to estrogen) can prevent bone loss and other menopausal symptoms in women who have recently gone through menopause.
- Conditions
- Menopause, Osteoporosis, Osteopenia
- Trial name
- SPARE (NCT00076050)
- Testing
- Soy isoflavones
- Where
- United States
- Volunteers
- 248 people, healthy volunteers welcome
- Sponsor
- University of Miami
Pulmonary Disease, Chronic Obstructive
Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.
This study will last up to 3 years. You will visit the clinic up to 14 times. Certain visits will include lung function tests and scans of your bones.
- Trial name
- NCT00355342
- Testing
- Salmeterol 50 mcg BID, Fluticasone Propionate/Salmeterol 250/50 mcg BID, DISKUS inhaler
- Where
- 37 sites in United States
- Volunteers
- 186 people
- Sponsor
- GlaxoSmithKline
Breast Neoplasms, Osteoporosis
Zoledronic Acid - Letrozole Adjuvant Synergy Trial (ZFAST) - Cancer Treatment Related Bone Loss in Postmenopausal Women With Estrogen Receptor Positive and/or Progesterone Receptor Positive Breast Cancer Receiving Adjuvant Hormonal Therapy
This protocol is designed to compare the effect on bone of Zoledronic Acid 4 mg every 6 months when given upfront versus delayed start (based on a post-baseline BMD T- Score below -2.0 SD at either the lumbar spine or total hip…
- Trial name
- NCT00050011
- Testing
- Zoledronic Acid, Letrozole
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 602 people
- Sponsor
- Novartis Pharmaceuticals